Kodiak Sciences Inc Common Stock KOD
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T02:09:33.475Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T00:53:39.27070869Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-13T02:09:32.895244+00:00
Kodiak Sciences Inc Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 121.02 | 78.0% | 12.4% | 98.95 | 82.2% | 10.6% |
| 25Δ | 118.77 | 78.7% | 10.8% | 101.14 | 80.7% | 9.0% |
| 30Δ | 116.88 | 80.1% | 9.5% | 103.00 | 79.9% | 7.8% |
| 35Δ | 114.99 | 81.6% | 8.3% | 104.86 | 79.0% | 6.6% |
| 40Δ | 113.20 | 79.8% | 7.2% | 106.49 | 78.8% | 5.8% |
| 45Δ | 111.41 | 78.1% | 6.0% | 108.09 | 78.6% | 5.0% |
| 50Δ | 109.67 | 76.6% | 5.0% | 109.70 | 78.5% | 4.3% |
| 55Δ | 108.11 | 76.5% | 4.3% | 111.64 | 82.0% | 3.7% |
| 60Δ | 106.55 | 76.4% | 3.6% | 113.65 | 86.4% | 3.3% |
| 65Δ | 104.99 | 76.3% | 2.9% | 115.70 | 89.2% | 2.8% |
| 70Δ | 103.29 | 75.7% | 2.4% | 117.84 | 88.5% | 2.3% |
| 75Δ | 101.60 | 75.2% | 1.9% | 119.97 | 87.8% | 1.7% |
| 80Δ | 99.89 | 74.5% | 1.4% | 123.04 | 89.3% | 1.3% |
20Δ
- Pseudo strike
- 121.02
- IV
- 78.0%
- B/E move
- 12.4%
- Pseudo strike
- 98.95
- IV
- 82.2%
- B/E move
- 10.6%
25Δ
- Pseudo strike
- 118.77
- IV
- 78.7%
- B/E move
- 10.8%
- Pseudo strike
- 101.14
- IV
- 80.7%
- B/E move
- 9.0%
30Δ
- Pseudo strike
- 116.88
- IV
- 80.1%
- B/E move
- 9.5%
- Pseudo strike
- 103.00
- IV
- 79.9%
- B/E move
- 7.8%
35Δ
- Pseudo strike
- 114.99
- IV
- 81.6%
- B/E move
- 8.3%
- Pseudo strike
- 104.86
- IV
- 79.0%
- B/E move
- 6.6%
40Δ
- Pseudo strike
- 113.20
- IV
- 79.8%
- B/E move
- 7.2%
- Pseudo strike
- 106.49
- IV
- 78.8%
- B/E move
- 5.8%
45Δ
- Pseudo strike
- 111.41
- IV
- 78.1%
- B/E move
- 6.0%
- Pseudo strike
- 108.09
- IV
- 78.6%
- B/E move
- 5.0%
50Δ
- Pseudo strike
- 109.67
- IV
- 76.6%
- B/E move
- 5.0%
- Pseudo strike
- 109.70
- IV
- 78.5%
- B/E move
- 4.3%
55Δ
- Pseudo strike
- 108.11
- IV
- 76.5%
- B/E move
- 4.3%
- Pseudo strike
- 111.64
- IV
- 82.0%
- B/E move
- 3.7%
60Δ
- Pseudo strike
- 106.55
- IV
- 76.4%
- B/E move
- 3.6%
- Pseudo strike
- 113.65
- IV
- 86.4%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 104.99
- IV
- 76.3%
- B/E move
- 2.9%
- Pseudo strike
- 115.70
- IV
- 89.2%
- B/E move
- 2.8%
70Δ
- Pseudo strike
- 103.29
- IV
- 75.7%
- B/E move
- 2.4%
- Pseudo strike
- 117.84
- IV
- 88.5%
- B/E move
- 2.3%
75Δ
- Pseudo strike
- 101.60
- IV
- 75.2%
- B/E move
- 1.9%
- Pseudo strike
- 119.97
- IV
- 87.8%
- B/E move
- 1.7%
80Δ
- Pseudo strike
- 99.89
- IV
- 74.5%
- B/E move
- 1.4%
- Pseudo strike
- 123.04
- IV
- 89.3%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 112.37% | |
| 119.12% | |
| 119.02% | |
| 125.10% | |
| 127.93% | |
| 129.15% | |
| 132.03% | |
| 132.20% | |
| 128.28% | |
| 126.35% | |
| 131.22% | |
| 135.08% | |
| 133.01% | |
| 133.05% | |
| 138.61% | |
| 139.84% | |
| 145.38% | |
| 149.66% | |
| 155.64% | |
| 150.25% | |
| 154.08% | |
| 158.25% | |
| 172.11% | |
| 182.56% | |
| 176.88% | |
| 187.86% | |
| 118.11% | |
| 93.35% | |
| 86.23% | |
| 82.40% | |
| 81.99% | |
| 80.76% | |
| 80.54% | |
| 74.59% | |
| 76.51% | |
| 75.94% | |
| 79.92% | |
| 77.32% | |
| 88.07% | |
| 81.28% | |
| 80.66% | |
| 78.90% | |
| 79.84% | |
| 80.01% | |
| 78.72% | |
| 79.19% | |
| 81.02% | |
| 82.69% | |
| 82.02% | |
| 82.41% |
Biotechnology
KPTI
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and…
More →KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from…
More →KRRO
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent…
More →KRYS
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company…
More →KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego,…
More →KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins…
More →